
|Articles|June 1, 2001
Pioneer in PSA test doubts its predictability
Palo Alto, CA-Urologists have heard more than once from detractors who have said that measuring PSA is not useful as a predictor for prostate cancer. You may now add Thomas A. Stamey, MD-the first investigator to show that the level of serum PSA was proportional to the volume of prostate cancer-to the list of naysayers.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD
2
Praful Ravi, MB, BChir, MRCP, on PSMA-PET during initial systemic therapy for mHSPC
3
Clint Bahler, MD, reflects on precision medicine and focal therapy highlights at AUA 2026
4
Study suggests potential diuretic effect with nadofaragene firadenovec
5











